Higher mortality in patients with milder autonomous cortisol secretion
- 1Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna
- 2Department of Laboratory Medicine, Medical University of Vienna
Abstract
Background: Current evidence highlights the need for appropriate diagnosis and therapy to improve outcomes in people with mild autonomous cortisol secretion (MACS). We aimed to validate the clinical sex-specific significance of the novel diagnosis MACS by characterizing patients according to morbidity and mortality in a real-world setting.
Methods: This retrospective single-center cohort study included clinical data from 670 adult patients with adrenal adenomas undergoing diagnostic workup regarding adrenal hypercortisolism at the Vienna General Hospital from 01.01.2000 to 31.12.2022. For mortality analyses, follow-up data spanning over 20 years was available, patients alive after 01.12.2024 were censored. Patients were classified into 3 groups based on post 1mg-DST cortisol levels (≤1.8µg/dL (suppressed 1mg-DST); >1.8 to ≤5µg/dl (mildly elevated 1mg-DST); >5µg/dL (markedly elevated 1mg-DST)) and analyzed according to cortisol-associated morbidity and mortality.
Results: Compared to those with suppressed 1mg-DST, patients with mildly elevated 1mg-DST were more frequently diagnosed with cortisol-associated diseases like cardiovascular disease (CVD) and osteoporosis while patients with markedly elevated 1mg-DST had more frequently arterial hypertension (aHTN) and osteoporosis, particularly women. Patients with mildly elevated 1mg-DST exhibited the highest mortality, despite comparable prevalence rates of cortisol-associated comorbidities between the mildly and the markedly elevated 1mg-DST group, even after adjusting for age, sex, BMI and cardiometabolic risk factors (HR 1.57 ( 95% CI: 1.01-2.45)). This was attenuated after additional adjustment for cancer history.
Conclusion: We identified the mildly elevated 1mg-DSTgroup as a high-risk formerly overlooked cohort, characterized by increased morbidity and mortality. Further prospective studies are needed to clarify the underlying mechanisms and the potential role of cortisol-specific treatment.
Related
- Prevalence of Mild Autonomous Cortisol Secretion Among Patients With Adrenal Incidentaloma and Its Association With Metabolic Abnormalities: A Hospital-Based, Analytical, Cross-Sectional Study
- Mild Autonomous Cortisol Secretion Is Associated with Computed Tomography-Derived Hepatic Steatosis in Patients with Adrenal Incidentaloma.
- Multi-omics profiling reveals molecular features of visceral adiposity in autonomous cortisol secretion
- Hair cortisol as a complementary marker of chronic glucocorticoid exposure in mild autonomous cortisol secretion.
- Retinal Microvascular and Peripapillary Profiles in Mild Autonomous Cortisol Secretion Versus Nonfunctioning Adrenal Adenomas
BibTeX
@article{bellach2026higher,
title = {{Higher mortality in patients with milder autonomous cortisol secretion}},
author = {Luise Bellach and Dorota Sluková and Dorothea Kalender and Sarah Hofer-Zeni and Liliana Gard and Sabina Baumgartner-Parzer and Rodrig Marculescu and Greisa Vila and Peter Wolf and Alexandra Kautzky-Willer and Michael Leutner},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.1913679},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1913679/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Higher mortality in patients with milder autonomous cortisol secretion
AU - Luise Bellach
AU - Dorota Sluková
AU - Dorothea Kalender
AU - Sarah Hofer-Zeni
AU - Liliana Gard
AU - Sabina Baumgartner-Parzer
AU - Rodrig Marculescu
AU - Greisa Vila
AU - Peter Wolf
AU - Alexandra Kautzky-Willer
AU - Michael Leutner
PY - 2026
DA - 2026/11/16
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1913679
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1913679/full
AB - Background: Current evidence highlights the need for appropriate diagnosis and therapy to improve outcomes in people with mild autonomous cortisol secretion (MACS). We aimed to validate the clinical sex-specific significance of the novel diagnosis MACS by characterizing patients according to morbidity and mortality in a real-world setting. Methods: This retrospective single-center cohort study included clinical data from 670 adult patients with adrenal adenomas undergoing diagnostic workup regarding adrenal hypercortisolism at the Vienna General Hospital from 01.01.2000 to 31.12.2022. For mortality analyses, follow-up data spanning over 20 years was available, patients alive after 01.12.2024 were censored. Patients were classified into 3 groups based on post 1mg-DST cortisol levels (≤1.8µg/dL (suppressed 1mg-DST); >1.8 to ≤5µg/dl (mildly elevated 1mg-DST); >5µg/dL (markedly elevated 1mg-DST)) and analyzed according to cortisol-associated morbidity and mortality. Results: Compared to those with suppressed 1mg-DST, patients with mildly elevated 1mg-DST were more frequently diagnosed with cortisol-associated diseases like cardiovascular disease (CVD) and osteoporosis while patients with markedly elevated 1mg-DST had more frequently arterial hypertension (aHTN) and osteoporosis, particularly women. Patients with mildly elevated 1mg-DST exhibited the highest mortality, despite comparable prevalence rates of cortisol-associated comorbidities between the mildly and the markedly elevated 1mg-DST group, even after adjusting for age, sex, BMI and cardiometabolic risk factors (HR 1.57 ( 95% CI: 1.01-2.45)). This was attenuated after additional adjustment for cancer history. Conclusion: We identified the mildly elevated 1mg-DSTgroup as a high-risk formerly overlooked cohort, characterized by increased morbidity and mortality. Further prospective studies are needed to clarify the underlying mechanisms and the potential role of cortisol-specific treatment.
SN - 1664-2392
ER -